查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1654322

全球上皮瘤藥物市場：市場規模、佔有率和趨勢分析（按類型、藥物類別、分銷管道和地區）、按細分市場預測（2025-2030 年）

Epithelioma Treatment Market Size, Share & Trends Analysis Report By Type, By Drug Class (Hedgehog Pathway Inhibitors, Immune Checkpoint Inhibitors), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

上皮瘤藥物市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球上皮瘤治療市場規模預計到2030年將達到97.3億美元，2025年至2030年複合年成長率為10.4%。

皮膚癌，尤其是基底細胞癌（BCC）和鱗狀細胞癌（SCC）發生率的增加是推動市場擴張的主要因素。根據美國癌症協會統計，預計2024年美國將出現約100,640例黑色素瘤新病例，其中男性約59,170例，女性約41,470例。此外，預計約有 8,290 人死亡，其中包括 5,430 名男性和 2,860 名女性。患病率的上升刺激了對先進治療的需求，從而促進了市場的成長。

醫療技術的進步也扮演著重要角色。免疫查核點抑制劑（如Pembrolizumab、 Nivolumab）和標靶治療（如用於治療 BCC 的 vismodegib）等創新治療方法的開發正在改變治療選擇，為患者帶來新的希望並擴大市場機會。這些進展得到了良好的臨床試驗結果和 FDA核准的進一步支持，強調了這些治療的有效性和安全性。

監管和政府措施對於塑造市場也至關重要。在美國，FDA 對有前景的治療方法的快速核准流程有助於更快地獲得新治療方法。此外，在歐洲，歐洲藥品管理局（EMA）等舉措為新藥的開發和核准提供了重要支持。政府對癌症研究的資助以及增強早期發現和治療的公眾意識提升宣傳活動進一步推動了市場成長。

上皮瘤藥物市場：概述

  • 根據類型，基底細胞上皮瘤將佔據市場主導地位，到 2024 年將佔 61.0% 的佔有率。 BCC 是一種基底細胞上皮瘤，是世界上最常見的皮膚癌類型。
  • 根據藥物類別，Hedgehog通路抑制劑有望在 2024 年獲得超過 41.2% 的最大銷售佔有率。這種優勢歸因於這些抑制劑在治療 BCC 方面的功效、皮膚癌發病率的增加以及藥物開發方面的最新重大進展。
  • 根據銷售管道，醫院藥局部門在 2024 年引領市場，獲得超過 51.8% 的顯著收益佔有率。
  • 預計北美上皮瘤藥物市場將在 2024 年佔據全球市場的主導地位，收益佔有率為 37.5%，這主要得益於皮膚癌的高發病率和完善的醫療保健基礎設施。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

3. 上皮腫瘤藥物市場：促進因素、趨勢與範圍

  • 市場聯動展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 商業環境分析
    • 產業分析：波特五力分析
    • PESTEL 分析

第 4 章上皮腫瘤治療市場：按類型分類的業務分析

  • 按類型分類的市場佔有率（2024 年和 2030 年）
  • 按類型分類的儀表板
  • 按類型分類的市場規模預測及趨勢分析（2018-2030）
  • 基底細胞上皮瘤
  • 鱗狀細胞腫瘤
  • 其他

5. 上皮腫瘤藥物市場：依藥物類別的業務分析

  • 按藥物類別分類的市場佔有率（2024 年和 2030 年）
  • 藥品類別儀表板
  • 依藥物類別分類的市場規模預測及趨勢分析（2018-2030年）
  • Hedgehog 路徑抑制劑
  • 免疫查核點抑制劑
  • 化療藥物
  • 其他

第 6 章 上皮腫瘤藥物市場：按分銷管道進行的業務分析

  • 按分銷管道分類的市場佔有率（2024 年和 2030 年）
  • 分銷通路儀表板
  • 按分銷管道分類的市場規模預測及趨勢分析（2018-2030 年）
  • 醫院藥房
  • 零售藥局
  • 其他

第7章 上皮腫瘤藥物市場：按地區分類的估計和趨勢分析

  • 各地區市場佔有率（2024 年及 2030 年）
  • 市場儀表板：按地區
  • 市場規模預測及趨勢分析（2018-2030年）
  • 北美洲
    • 按國家/地區分類（2018-2030 年）
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 按國家/地區分類（2018-2030 年）
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 按國家/地區分類（2018-2030 年）
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 按國家/地區分類（2018-2030 年）
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 按國家/地區分類（2018-2030 年）
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 參與企業概況
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Bristol-Myers Squibb Company
    • Merck &Co., Inc.
    • Novartis AG
    • Amgen Inc.
    • Pfizer Inc.
    • Sanofi
    • Johnson &Johnson Services, Inc.
    • F. Hoffmann-La Roche Ltd
Product Code: GVR-4-68040-446-0

Epithelioma Treatment Market Growth & Trends:

The global epithelioma treatment market size is expected to reach USD 9.73 billion by 2030, registering a CAGR of 10.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing incidence of skin cancers, notably basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), is a major driver of market expansion. According to the American Cancer Society, the U.S. is expected to see approximately 100,640 new cases of melanoma in 2024, with around 59,170 in men and 41,470 in women. Additionally, melanoma is anticipated to cause about 8,290 deaths, including 5,430 men and 2,860 women. This escalating prevalence underscores the increasing demand for advanced treatments and contributes significantly to the market's growth.

Advancements in medical technology also play a crucial role. The development of innovative therapies, such as immune checkpoint inhibitors (e.g., pembrolizumab and nivolumab) and targeted therapies (e.g., vismodegib for BCC), has revolutionized treatment options, offering new hope for patients and expanding market opportunities. These advancements are further supported by positive clinical trial results and FDA approvals, which underscore the efficacy and safety of these treatments.

Regulatory bodies and government initiatives are also pivotal in shaping the market. In the U.S., the FDA's accelerated approval process for promising treatments facilitates faster access to new therapies. Additionally, initiatives like the European Medicines Agency (EMA) provide crucial support in developing and approving new drugs in Europe. Government funding for cancer research and public awareness campaigns are enhancing early detection and treatment, further driving market growth.

Epithelioma Treatment Market Report Highlights:

  • Based on type, basal cell epithelioma dominated the market and accounted for a share of 61.0% in 2024. BCC, a type of basal cell epithelioma, is the most common form of skin cancer globally.
  • Based on drug class, the hedgehog pathway inhibitors segment secured the largest revenue share of over 41.2% in 2024. This prominence is attributed to the efficacy of these inhibitors in treating BCC, the increasing incidence of skin cancers, and significant recent advancements in drug development.
  • Based on distribution channel, The hospital pharmacies segment led the market in 2024, capturing a substantial revenue share of over 51.8%.
  • North America epithelioma treatment market dominated the global market with a revenue share of 37.5% in 2024, largely fueled by the high incidence of skin cancers and a well-established healthcare infrastructure.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Drug Class
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Epithelioma Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Epithelioma Treatment Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Basal Cell Epithelioma
    • 4.4.1. Basal Cell Epithelioma Market, 2018 - 2030 (USD Million)
  • 4.5. Squamous Cell Epithelioma
    • 4.5.1. Squamous Cell Epithelioma Market, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Epithelioma Treatment Market: Drug Class Business Analysis

  • 5.1. Drug Class Market Share, 2024 & 2030
  • 5.2. Drug Class Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 5.4. Hedgehog Pathway Inhibitors
    • 5.4.1. Hedgehog Pathway Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.5. Immune Checkpoint Inhibitors
    • 5.5.1. Immune Checkpoint Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.6. Chemotherapeutic Agents
    • 5.6.1. Chemotherapeutic Agents Market, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Epithelioma Treatment Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Epithelioma Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 7.4. North America
    • 7.4.1. North America Epithelioma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Epithelioma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Epithelioma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Epithelioma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Epithelioma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Bristol-Myers Squibb Company
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Merck & Co., Inc.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Novartis AG
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Amgen Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Pfizer Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Sanofi
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Johnson & Johnson Services, Inc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. F. Hoffmann-La Roche Ltd
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global epithelioma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 5 Global epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 6 Global epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 North America epithelioma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 9 North America epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 North America epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 U.S epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 12 U.S epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 U.S Epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 14 Canada epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 15 Canada epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 16 Canada epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17 Mexico epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 18 Mexico epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 19 Mexico epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Europe epithelioma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 21 Europe epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 22 Europe epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 Europe epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 UK epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 25 UK epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 26 UK Epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 27 Germany epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 28 Germany epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Germany epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 France epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 31 France epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 France Epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 Italy epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 34 Italy epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 35 Italy epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36 Spain epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 37 Spain epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Spain epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 Norway epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 40 Norway epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 41 Norway Epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42 Denmark epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 43 Denmark epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 44 Denmark epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Sweden epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 46 Sweden epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 47 Sweden epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific epithelioma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 Japan epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 53 Japan epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 54 Japan epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55 China epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 56 China epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 57 China epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58 India epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 59 India epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 60 India epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Australia epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 62 Australia epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 63 Australia epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64 South Korea epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 65 South Korea epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 66 South Korea epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67 Thailand epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 68 Thailand epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 69 Thailand epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 Latin America epithelioma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 71 Latin America epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 72 Latin America epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 73 Latin America epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 Brazil epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 75 Brazil epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 76 Brazil epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77 Argentina epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 78 Argentina epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 79 Argentina epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Epithelioma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84 South Africa epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 85 South Africa epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 86 South Africa epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 UAE epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 91 UAE epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 92 UAE epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 93 Kuwait epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 94 Kuwait epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 95 Kuwait epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Epithelioma treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Type and drug class outlook (USD Million)
  • Fig. 10 Distribution channel outlook (USD Million)
  • Fig. 11 Competitive landscape
  • Fig. 12 Epithelioma treatment market dynamics
  • Fig. 13 Epithelioma treatment market: Porter's five forces analysis
  • Fig. 14 Epithelioma treatment market: PESTLE analysis
  • Fig. 15 Epithelioma treatment market: Type segment dashboard
  • Fig. 16 Epithelioma treatment market: Type market share analysis, 2024 & 2030
  • Fig. 17 Basal cell epithelioma market, 2018 - 2030 (USD Million)
  • Fig. 18 Squamous cell epithelioma market, 2018 - 2030 (USD Million)
  • Fig. 19 Others market, 2018 - 2030 (USD Million)
  • Fig. 20 Epithelioma treatment market: Drug class segment dashboard
  • Fig. 21 Epithelioma treatment market: Drug class market share analysis, 2024 & 2030
  • Fig. 22 Hedgehog pathway inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 23 Immune checkpoint inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 24 Chemotherapeutic agents market, 2018 - 2030 (USD Million)
  • Fig. 25 Others market, 2018 - 2030 (USD Million)
  • Fig. 26 Epithelioma treatment market: Distribution channel segment dashboard
  • Fig. 27 Epithelioma treatment market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 28 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 29 Retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 30 Others market, 2018 - 2030 (USD Million)
  • Fig. 31 Epithelioma treatment market revenue, by region
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 Regional marketplace: Key takeaways
  • Fig. 34 North America epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. country dynamics
  • Fig. 36 U.S. epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 Canada country dynamics
  • Fig. 38 Canada epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 Mexico country dynamics
  • Fig. 40 Mexico epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 Europe epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 42 UK country dynamics
  • Fig. 43 UK epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 Germany country dynamics
  • Fig. 45 Germany epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 France country dynamics
  • Fig. 47 France epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 Italy country dynamics
  • Fig. 49 Italy epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 Spain country dynamics
  • Fig. 51 Spain epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Norway country dynamics
  • Fig. 53 Norway epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 Sweden country dynamics
  • Fig. 55 Sweden epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 Denmark country dynamics
  • Fig. 57 Denmark epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 Asia Pacific epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 59 Japan country dynamics
  • Fig. 60 Japan epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 61 China country dynamics
  • Fig. 62 China epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 63 India country dynamics
  • Fig. 64 India epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 65 Australia country dynamics
  • Fig. 66 Australia epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 67 South Korea country dynamics
  • Fig. 68 South Korea epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 69 Thailand country dynamics
  • Fig. 70 Thailand epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 71 Latin America epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 72 Brazil country dynamics
  • Fig. 73 Brazil epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 74 Argentina country dynamics
  • Fig. 75 Argentina epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 76 MEA epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 77 South Africa country dynamics
  • Fig. 78 South Africa epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 79 Saudi Arabia country dynamics
  • Fig. 80 Saudi Arabia epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 81 UAE country dynamics
  • Fig. 82 UAE epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 83 Kuwait country dynamics
  • Fig. 84 Kuwait epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 85 Company categorization
  • Fig. 86 Company market position analysis
  • Fig. 87 Strategic framework